# Becton Dickinson (BDX) Q4 FY2026 earnings

Results filed 2026-11-05 for the quarter ended 2026-09-29. Source page: https://earnings.opennash.com/companies/bdx/2026-q4/
Press release and documents: https://www.sec.gov/Archives/edgar/data/10795/000162828026070511/0001628280-26-070511-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

BD signed a U.S. government manufacturing partnership with $19 billion of planned investment and Section 232 tariff relief, while launching new vascular and tissue-regeneration products as New BD.

BD finished its transformation into a four-segment MedTech company after spinning off its Biosciences and Diagnostic Solutions business into Waters in February. Growth was led by Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa. Interventional grew fastest of the four segments. Connected Care lagged as Alaris infusion pump capital sales fell. BD also won U.S. launch clearance for new vascular and hernia products.
Management is steering toward faster innovation, commercial investment in growth platforms and BD Excellence productivity work, and plans to detail the strategy at its December 10 Investor Day. The U.S. Government partnership brings a $19 billion investment plan and conditional tariff relief. The tension is that fiscal 2027 growth is guided to low single digits, with about 200 bps of drag from Alaris capital, so growth platforms must offset a weaker pump cycle.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Q4 revenue | $5.3 billion | increased 5.4% as reported, 5.6% FXN | GAAP |
| Q4 diluted EPS | $2.52 | up 110.0% from a year ago | GAAP |
| Q4 adjusted diluted EPS | $4.15 | up 27.3% from a year ago | non-GAAP |
| FY26 cash from continuing operations | $3.6 billion | increased 30.0% | GAAP |
| FY26 free cash flow | $2.9 billion | increased 42.5% | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Medical Essentials | $1,786 | up 5.9% reported, 5.9% FXN |
| Connected Care | $1,269 | up 1.6% reported, 2.1% FXN |
| BioPharma Systems | $748 | up 6.5% reported, 7.0% FXN |
| Interventional | $1,472 | up 7.6% reported, 7.6% FXN |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted diluted EPS | fiscal 2027 | $13.10 to $13.30 |

## Key takeaways

1. **U.S. government partnership anchors domestic manufacturing push** BD intends to invest $19 billion in the U.S. over several years, with $3 billion directed toward manufacturing expansion. The agreement also provides relief from future Section 232 tariffs on covered products, subject to final scope and BD meeting agreed milestones.
2. **Interventional launches broaden BD's addressable markets** BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27, entering a $2B global venous market, and received 510(k) clearance for Phasix ST Parastomal Hernia Mesh. Revello covered stent iliac data from the AGILITY trial were positive.
3. **Advanced Patient Monitoring is a standout growth engine** APM grew 17.3% FXN in Q4, led by HemoSphere Alta and Acumen IQ products. BD credits sales force investment and says HemoSphere Alta had strong uptake.
4. **Alaris share gains coexist with a capital headwind** BD Alaris gained additional share in Q4, and Medication Management Solutions grew mid-single digits excluding Alaris. Even so, FY27 guidance carries about a 200 bps Alaris capital headwind, and Connected Care grew only 2.1% FXN.
5. **BioPharma Systems rides GLP-1 demand in biologic delivery** BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength and healthy utilization. A moderating vaccine headwind partly offset it, and BD says it is expanding its position in next-generation biologic drug delivery.

## Questions

**What is BD's U.S. Government partnership?** BD intends to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion, to strengthen domestic supply chains for essential medical consumables. It also provides relief from future Section 232 tariffs on covered products, subject to final scope and milestones.
**Which BD products drove growth this quarter?** Advanced Patient Monitoring grew 17.3% FXN, led by HemoSphere Alta and Acumen IQ. PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa also grew at double-digit rates.
**What new products did BD launch or win clearance for?** BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27 after an EU launch in Q3 FY26. It received 510(k) clearance for Phasix ST Parastomal Hernia Mesh, with a U.S. launch expected in 1H FY27.
**How is BD positioned in GLP-1 and biologic drug delivery?** BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength. Management says it is expanding its position in next-generation biologic drug delivery.
**What does BD expect for fiscal 2027?** BD guides to low single-digit FXN revenue growth, including about a 200 bps Alaris capital headwind, and adjusted EPS of $13.10 to $13.30. Q1 revenue growth is expected at the low end of the range, and BD will hold an Investor Day on December 10.

## Slides and investor documents

- [Presentation     PDF](https://d1io3yog0oux5.cloudfront.net/_d324fc005b8ca00e706abb425b4a58c6/bd/db/2447/24531/presentation/Q4_FY26_Earnings_Presentation_vFINAL.pdf) (Slide deck)

